623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12F.P. Lin, David M. Thomas, S. Chinchen et al.|Annals of Oncology|2024Cited by 1
996P Phase II trial of alectinib in ALK-altered solid tumours and NSCLC with negative standard care testing: Australian molecular screening and therapeutics (MoST) substudy 14Frank Lin, D. Thomas, M. Itchins et al.|Annals of Oncology|2025Cited by 0